Revenue (Quarterly) Chart

View Revenue (Quarterly) for ECVT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
March 31, 2026 214.95M
December 31, 2025 199.40M
September 30, 2025 204.91M
June 30, 2025 200.13M
March 31, 2025 143.11M
December 31, 2024 148.90M
September 30, 2024 153.87M
June 30, 2024 182.82M
March 31, 2024 160.54M
December 31, 2023 172.80M
September 30, 2023 173.33M
June 30, 2023 184.11M
March 31, 2023 160.87M
December 31, 2022 182.80M
September 30, 2022 232.53M
June 30, 2022 225.17M
March 31, 2022 179.71M
December 31, 2021 170.20M
September 30, 2021 167.43M
June 30, 2021 146.95M
March 31, 2021 126.62M
Date Value
December 31, 2020 124.10M
September 30, 2020 130.68M
June 30, 2020 115.64M
March 31, 2020 125.55M
December 31, 2019 283.50M
September 30, 2019 423.80M
June 30, 2019 431.68M
March 31, 2019 359.22M
December 31, 2018 380.10M
September 30, 2018 427.20M
June 30, 2018 434.71M
March 31, 2018 366.20M
December 31, 2017 358.07M
September 30, 2017 391.83M
June 30, 2017 389.27M
March 31, 2017 332.93M
December 31, 2016 322.73M
September 30, 2016 369.98M
June 30, 2016 277.55M
March 31, 2016 93.91M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
Olin Corp. 1.583B
Stepan Co. 604.51M
Ascent Industries Co. 19.42M
Solesence, Inc. 12.96M
BioLargo, Inc. 1.115M